What is EvoEndo?
Founded in 2017, EvoEndo operates at the intersection of medical device engineering and digital health. The company specializes in the development of sterile, single-use, flexible endoscopes designed to facilitate procedures without the need for traditional sedation. By integrating virtual reality-based patient distraction systems, EvoEndo addresses a significant pain point in gastroenterology and pediatric care, effectively reducing the risks and costs associated with anesthesia. This dual-modality approach positions the company as a disruptive force in the medical technology sector, aiming to improve patient outcomes while streamlining clinical workflows for healthcare providers.
How much funding has EvoEndo raised?
EvoEndo has raised a total of $18.5M across 2 funding rounds:
Private Equity
$10.1M
Series A
$8.4M
Private Equity (2021): $10.1M, investors not publicly disclosed
Series A (2022): $8.4M led by Sunshine Charitable Foundation and TLP Investment Partners
Key Investors in EvoEndo
Sunshine Charitable Foundation
A philanthropic organization focused on supporting medical research and innovative healthcare solutions that improve patient quality of life.
TLP Investment Partners
A private investment firm specializing in growth-stage capital for healthcare and life sciences companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for EvoEndo?
With this major enterprise-level funding, EvoEndo is well-positioned to accelerate its regulatory and commercialization efforts. The strategic allocation of these resources will likely focus on scaling manufacturing capabilities for its single-use endoscope systems and expanding clinical trials to support broader market adoption. As the company moves beyond the preclinical stage, the focus will shift toward establishing robust distribution channels and securing further clinical validation. Investors are closely monitoring the firm's ability to integrate its VR distraction technology into standard hospital protocols, which could redefine the standard of care for endoscopic diagnostics and therapeutic interventions globally.
See full EvoEndo company page
